Clinical Trials in California

Showing 1601-1620 of 9,745 trials

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid Tumors

NCT05287399

This is a Phase 1, open-label, multicenter, single-arm, dose escalation study, designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of single-agent ASC61(an orally bioavailable small-molecule inhibitor of PD-L1) in subjects with advanced solid tumors for whom no standard therapy is available.

Advanced Solid Tumors

Ascletis Pharmaceuticals Co., Ltd.18 participantsStarted Aug 2022

Encinitas, California, United States • Fresno, California, United States • San Marcos, California, United States +1 more locations

Active Not RecruitingPhase 244 miles

A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease

NCT06538116

The main purpose of this study is to look at how safe the study drug (mevidalen) is and whether it works to alleviate symptoms when given to people with mild to moderate Alzheimer Disease (AD) dementia. This is done by looking at participants: thinking and memory (cognition), everyday activities and sleep, AD symptoms, physical activity, irritability or anxiety. The study is expected to last approximately 26 weeks and may include up to 14 visits.

Alzheimer Disease

Eli Lilly and Company300 participantsStarted Aug 2024

Phoenix, Arizona, United States • Little Rock, Arkansas, United States • Carlsbad, California, United States +61 more locations

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid Tumors

A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease

Find Trials by Condition in California

Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products

A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults With Fragile X Syndrome

A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies

A Phase 1/2 Study of AURN001 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction (ABA-1)

A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)

Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer

Implementing Scalable, PAtient-centered, Team-based, Technology-enabled Care for Adults With Type 2 Diabetes (iPATH)

LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers

A Multicenter, Prospective Blood Collection Study in a Kidney Transplant Population

A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors

Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma

A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS

Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors